Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06578195

ASSESS ALL ALS Study

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases.

ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHALS-CCT, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for ALS participants:

  • Age 18 years or older
  • Capable of providing informed consent
  • Willing to follow study procedures
  • Diagnosis of ALS by a physician
  • Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)

Inclusion criteria

for control participants:

  • Age 18 years or older
  • Capable of providing informed consent
  • Willing to follow study procedures
  • No diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS)
  • No history of familial ALS/Frontotemporal Dementia (FTD) in a close family member** unless the participant has previously tested negative for the known causative ALS genes. Participants with a family history of singleton ALS are permitted to enroll.
  • ** Defined by the presence of a known ALS causative gene such as C9orf72 in a family member or a family history suggestive of an inherited ALS/FTD syndrome defined by two family members with a history of ALS and/or FTD.
  • Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)

Exclusion criteria

for all participants:

  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression <= 90 days of screening, that would interfere with the study procedure, according to Investigator's judgement.
  • Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment.

Exclusion criteria

for participants undergoing optional Lumbar Puncture

  • Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
  • Allergy to Lidocaine or other local anesthetic agents.
  • Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
  • Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
  • Current pregnancy based on participant self-report
  • Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures.

Treatment and study plan

Primary outcomes

  1. ALS Functional Rating Scale-Revised (ALSFRS-R)

    Time frame: Baseline, 4, 8, 12, 16, 20 and 24 months for ALS participants only.

    Questionnaire administered by a clinician that includes a series of questions about participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

  2. ALS Functional Rating Scale-Revised Self entry (ALSFRS-RSE)

    Time frame: Baseline, 2, 4 ,6, 8, 10, 12, 14,16, 18,20, 22 and 24 months for ALS participants only

    Questionnaires completed by participants that includes questions about participants ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

Secondary outcomes

  1. ALS Impairment Multidomain scale (AIMS)

    Time frame: 1, 3, 5,7,9,11,13,15,17,19,21 and 23 months from baseline for ALS participants only

    Questionnaires completed by participants that assess severity of the ALS disease

  2. Social Determinants of Health

    Time frame: Months 3 and 4 for all cohorts

    Questionnaires completed by participants that includes questions about non-medical factors that affect health outcomes

  3. Environmental History

    Time frame: Month 1 for all cohorts

    Questionnaires completed by participants that includes questions about environmental exposures such as chemicals, smoking, alcohol etc.

  4. Cognitive assessment (ECAS)

    Time frame: Baseline, 12 and 24 months for all cohorts

    ECAS is a multi-domain assessment administered by study staff, to evaluate different aspects of cognitive function

  5. Vital Capacity

    Time frame: Baseline, 4,8,12,16,20 and 24 months for on-site ALS participants; Baseline, 12 and 24 months for control participants

    Change in respiratory function over time as measured by Slow Vital Capacity (SVC).

  6. Digital Speech Assessment

    Time frame: Baseline, and monthly (at month 1,2, 3 through month 24 from baseline)

    Participants will be asked to record voice samples at home once a month using a digital application installed on their device.

  7. HHD of 3 hand muscles bilaterally

    Time frame: Baseline, 4,8,12,16,20 and 24 months for on-site ALS participants; Baseline, 12 and 24 months for control participants

    Hand-held dynamometry (HHD) will be used as a quantitative measure of muscle strength for the three intrinsic hand muscles, bilaterally

Study contacts

Contact information is provided by the study sponsor or research team.

ALL ALS Patient Navigator

CONTACT

[email protected]

602-845-0248

Sponsors and collaborators

Lead sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Other

Collaborators

  • Foundation for the National Institutes of Health
  • Massachusetts General Hospital
  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Official study title

ASSESS ALL ALS - Longitudinal Biomarker Study for Symptomatic ALS and Control Participants

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Aug 29, 2024
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.